Grady Burnett biography
Grady Burnett serves as Independent Director of the Company. Mr. Burnett currently serves as the General Partner at Bow Capital, an early stage venture capital firm, a position he has held since co-founding the company in July 2016. Previously, he served as the President and Chief Operating Officer of HackerRank, a technology company, from September 2015 until July 2016. Before that, from September 2013 until October 2014, Mr. Burnett served as the Chief Operating Officer of Flurry, Inc., a mobile analytics, monetization and advertising company. Mr. Burnett has also served as Vice President of Global Sales and Operations at Facebook, Inc. from 2009 to 2013 and was also previously the Director of North American Sales and Operations for Google LLC’s AdWords team.
What is the salary of Grady Burnett?
As the Independent Director of Kaleido Biosciences Inc, the total compensation of Grady Burnett at Kaleido Biosciences Inc is $46,250. There are 8 executives at Kaleido Biosciences Inc getting paid more, with Jerald Korn having the highest compensation of $1,505,420.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Grady Burnett?
Grady Burnett is 47, he's been the Independent Director of Kaleido Biosciences Inc since 2018. There are 13 older and 3 younger executives at Kaleido Biosciences Inc. The oldest executive at Kaleido Biosciences Inc is Anne Prener, 62, who is the Independent Director.
What's Grady Burnett's mailing address?
Grady's mailing address filed with the SEC is C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Insiders trading at Kaleido Biosciences Inc
Over the last 6 years, insiders at Kaleido Biosciences Inc have traded over $0 worth of Kaleido Biosciences Inc stock and bought 3,273,186 units worth $32,952,342 . The most active insiders traders include Ventures Fund Iv General Pa..., Joshua T Brumm, eVentures Fund V General Par.... On average, Kaleido Biosciences Inc executives and independent directors trade stock every 119 days with the average trade being worth of $55. The most recent stock trade was executed by Daniel L Menichella on 8 February 2021, trading 20,000 units of KLDO stock currently worth $230,000.
What does Kaleido Biosciences Inc do?
the next breakthrough microbiome company from flagship venturelabs – the innovation foundry of flagship ventures – is coming.
What does Kaleido Biosciences Inc's logo look like?
Kaleido Biosciences Inc executives and stock owners
Kaleido Biosciences Inc executives and other stock owners filed with the SEC include:
-
Jerald Korn,
General Counsel, Corporate Secretary -
Katharine Knobil,
Chief Medical Officer and Head of Research and Development -
William E. Duke Jr.,
Chief Financial Officer -
Daniel L. Menichella B.A., M.B.A.,
Pres, CEO & Director -
Jean Mixer,
Independent Director -
Theo Melas-Kyriazi,
Independent Director -
Michael Bonney,
Chairman of the Board -
Anthony Quinn,
Independent Director -
Grady Burnett,
Independent Director -
Bonnie Bassler,
Independent Director -
Anne Prener,
Independent Director -
William Duke,
Chief Financial Officer -
Daniel Menichella,
President, Chief Executive Officer, Principal Executive Officer -
Dr. Alison Long M.D., Ph.D.,
Chief Medical Officer -
Dr. Mark A. Wingertzahn Ph.D.,
Sr. VP of R&D and Head of Devel. -
Susan Stewart J.D.,
Chief Regulatory Affairs  Advisor -
Dr. Johan Van Hylckama Vlieg Ph.D.,
Chief Scientific Officer -
Kimberly Hocknell,
Sr. VP of Technical Operations -
Jerald Korn J.D.,
COO, Gen. Counsel & Corp. Sec. -
Dr. Geoffrey von Maltzahn Ph.D.,
Co-Founder & Director -
Hylckama Vlieg Johan Van,
Chief Scientific Officer -
Ventures Fund Iv General Pa...,
-
Joshua T Brumm,
See Remarks -
Alison Frances Lawton,
See Remarks -
Maltzahn Geoffrey Von,
Director -
Ventures Fund V General Par...,
-
Ventures Fund Iv General Pa...,
-
Ventures Fund Iv General Pa...,
-
Alison S Long,
Chief Medical Officer